Adicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics Conference

Preclinical study shows Adicet’s Allogeneic Gamma Delta T Cell Platform may be a Promising Approach for Prostate Cancer

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced a poster presentation at the upcoming 2023 International Conference on Molecular Targets and Cancer Therapeutics hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer to be held in Boston from October 11-15, 2023.

Details of the poster presentation is as follows:

Abstract Title: Characterization of Allogeneic CAR γδ1 T Cell Therapy for Prostate Cancer Targeting a Novel Dimeric Epitope on PSMA (Prostate-Specific Membrane Antigen)

Poster Number: C117

Presenting Author: Nitya Ramadoss, PhD

Date/Time: Saturday, October 14, from 12:30 p.m. - 4:00 p.m. PDT

Session Location: Level 2, Exhibit Hall D

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs) and chimeric antigen adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231004175869/en/